company background image
HAE

Haemonetics NYSE:HAE Stock Report

Last Price

US$83.72

Market Cap

US$4.2b

7D

-1.4%

1Y

56.6%

Updated

08 Dec, 2022

Data

Company Financials +
HAE fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance5/6
Financial Health3/6
Dividends0/6

HAE Stock Overview

Haemonetics Corporation, a healthcare company, provides medical products and solutions.

Haemonetics Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Haemonetics
Historical stock prices
Current Share PriceUS$83.72
52 Week HighUS$86.58
52 Week LowUS$43.50
Beta0.36
1 Month Change-0.31%
3 Month Change8.91%
1 Year Change56.57%
3 Year Change-28.55%
5 Year Change46.62%
Change since IPO1,310.02%

Recent News & Updates

Haemonetics Q2 2023 Earnings Preview

Nov 04

Recent updates

Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

Oct 04
Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Aug 10
A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly

Jul 03
Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly

Calculating The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

May 11
Calculating The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Is Haemonetics (NYSE:HAE) Using Too Much Debt?

Apr 01
Is Haemonetics (NYSE:HAE) Using Too Much Debt?

Calculating The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Jan 28
Calculating The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Is Haemonetics (NYSE:HAE) Using Too Much Debt?

Dec 20
Is Haemonetics (NYSE:HAE) Using Too Much Debt?

Is Haemonetics Corporation (NYSE:HAE) Worth US$68.5 Based On Its Intrinsic Value?

Oct 28
Is Haemonetics Corporation (NYSE:HAE) Worth US$68.5 Based On Its Intrinsic Value?

Haemonetics (NYSE:HAE) Is Doing The Right Things To Multiply Its Share Price

Oct 09
Haemonetics (NYSE:HAE) Is Doing The Right Things To Multiply Its Share Price

We Think Haemonetics (NYSE:HAE) Is Taking Some Risk With Its Debt

Sep 07
We Think Haemonetics (NYSE:HAE) Is Taking Some Risk With Its Debt

Here's Why Shareholders May Want To Be Cautious With Increasing Haemonetics Corporation's (NYSE:HAE) CEO Pay Packet

Jul 31
Here's Why Shareholders May Want To Be Cautious With Increasing Haemonetics Corporation's (NYSE:HAE) CEO Pay Packet

Are Haemonetics Corporation (NYSE:HAE) Investors Paying Above The Intrinsic Value?

Jul 15
Are Haemonetics Corporation (NYSE:HAE) Investors Paying Above The Intrinsic Value?

Haemonetics (NYSE:HAE) Is Experiencing Growth In Returns On Capital

Jun 30
Haemonetics (NYSE:HAE) Is Experiencing Growth In Returns On Capital

Is Haemonetics (NYSE:HAE) A Risky Investment?

Jun 07
Is Haemonetics (NYSE:HAE) A Risky Investment?

Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 34%?

Apr 09
Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 34%?

There's Been No Shortage Of Growth Recently For Haemonetics' (NYSE:HAE) Returns On Capital

Mar 27
There's Been No Shortage Of Growth Recently For Haemonetics' (NYSE:HAE) Returns On Capital

Is Now The Time To Put Haemonetics (NYSE:HAE) On Your Watchlist?

Mar 14
Is Now The Time To Put Haemonetics (NYSE:HAE) On Your Watchlist?

Haemonetics (NYSE:HAE) Has A Pretty Healthy Balance Sheet

Mar 01
Haemonetics (NYSE:HAE) Has A Pretty Healthy Balance Sheet

What Can We Learn About Haemonetics' (NYSE:HAE) CEO Compensation?

Feb 17
What Can We Learn About Haemonetics' (NYSE:HAE) CEO Compensation?

Can You Imagine How Elated Haemonetics' (NYSE:HAE) Shareholders Feel About Its 330% Share Price Gain?

Feb 05
Can You Imagine How Elated Haemonetics' (NYSE:HAE) Shareholders Feel About Its 330% Share Price Gain?

Shareholder Returns

HAEUS Medical EquipmentUS Market
7D-1.4%-1.1%-2.8%
1Y56.6%-20.9%-19.6%

Return vs Industry: HAE exceeded the US Medical Equipment industry which returned -22.9% over the past year.

Return vs Market: HAE exceeded the US Market which returned -21.2% over the past year.

Price Volatility

Is HAE's price volatile compared to industry and market?
HAE volatility
HAE Average Weekly Movement4.0%
Medical Equipment Industry Average Movement8.9%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: HAE is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: HAE's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19712,821Chris Simonhttps://www.haemonetics.com

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Haemonetics Corporation Fundamentals Summary

How do Haemonetics's earnings and revenue compare to its market cap?
HAE fundamental statistics
Market CapUS$4.24b
Earnings (TTM)US$86.05m
Revenue (TTM)US$1.08b

49.2x

P/E Ratio

3.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HAE income statement (TTM)
RevenueUS$1.08b
Cost of RevenueUS$491.12m
Gross ProfitUS$592.60m
Other ExpensesUS$506.55m
EarningsUS$86.05m

Last Reported Earnings

Oct 01, 2022

Next Earnings Date

n/a

Earnings per share (EPS)1.70
Gross Margin54.68%
Net Profit Margin7.94%
Debt/Equity Ratio112.3%

How did HAE perform over the long term?

See historical performance and comparison